Glucagon (19-29), Human Mechanistic Insights, Clinical Value

Glucagon (19-29), Human: Mechanistic Insights, Clinical Value, and Research Applications

Introduction
Glucagon (19-29), human, is a synthetic peptide corresponding to the C-terminal fragment of the full-length human glucagon hormone, comprising amino acids 19 through 29. Glucagon itself is a 29-amino acid peptide hormone produced by the alpha cells of the pancreas, primarily involved in glucose homeostasis through its action on hepatic glucose production. The truncated fragment Glucagon (19-29) has garnered significant interest in recent years due to its distinct biological activities, which are separate from those of the full-length hormone. This peptide is increasingly utilized in research settings to elucidate the structure-function relationships of glucagon and its receptor, as well as to probe novel signaling pathways and therapeutic targets.

Mechanistically, Glucagon (19-29) is believed to interact with the glucagon receptor (GCGR), a class B G protein-coupled receptor (GPCR), albeit with altered affinity and efficacy compared to the full-length peptide (Mayo et al., 2003, J Biol Chem). The C-terminal region of glucagon is critical for receptor binding and activation, and studies have shown that truncated fragments such as Glucagon (19-29) can act as partial agonists or antagonists, modulating downstream signaling events including cyclic AMP (cAMP) production and protein kinase A (PKA) activation (Yang et al., 2016, Peptides). This unique pharmacological profile positions Glucagon (19-29) as a valuable tool for dissecting glucagon receptor pharmacology and for the development of novel therapeutic strategies targeting metabolic and non-metabolic diseases.

[Related: Roscovitine (Seliciclib,CYC202)] Clinical Value and Applications
The clinical value of Glucagon (19-29), human, lies primarily in its utility as a research tool rather than as a direct therapeutic agent. Its applications span several domains:

1. **Receptor Pharmacology:** By selectively engaging the glucagon receptor with altered efficacy, Glucagon (19-29) enables the study of receptor activation, desensitization, and downstream signaling pathways. This is crucial for understanding the molecular basis of glucagon action and for the rational design of receptor modulators (Mayo et al., 2003).

[Related: what does mg132 do] 2. **Metabolic Research:** Given the central role of glucagon in glucose metabolism, Glucagon (19-29) is employed in studies investigating hepatic glucose output, glycogenolysis, and gluconeogenesis. Its partial agonist/antagonist properties allow researchers to dissect the contributions of specific receptor domains to metabolic regulation (Yang et al., 2016).

3. **Peptide Structure-Function Studies:** The C-terminal fragment is instrumental in mapping the functional domains of glucagon. By comparing the biological activities of full-length and truncated peptides, researchers can identify critical residues for receptor binding and activation (Unson et al., 1989, J Biol Chem).

[Related: Phenyl sulfate] 4. **Drug Discovery:** Glucagon (19-29) serves as a template for the development of novel peptide-based therapeutics, including receptor antagonists for the treatment of hyperglucagonemia and related metabolic disorders such as type 2 diabetes (Capozzi et al., 2020, Diabetes).

5. **Assay Development:** The peptide is used as a standard or control in bioassays measuring glucagon receptor activity, cAMP production, and other downstream signaling events.

Key Challenges and Pain Points Addressed
Current treatments for metabolic disorders such as diabetes and obesity often target the insulin pathway, with limited focus on glucagon signaling. However, dysregulation of glucagon secretion and action contributes significantly to hyperglycemia and impaired glucose homeostasis in these conditions (Unger & Cherrington, 2012, Diabetes). Traditional glucagon receptor antagonists have been associated with adverse effects, including increased hepatic fat accumulation and elevated transaminases (Kazda et al., 2016, Diabetes Obes Metab).

Glucagon (19-29) addresses several key challenges:

- **Selective Modulation:** As a truncated peptide, Glucagon (19-29) allows for selective modulation of the glucagon receptor, providing insights into receptor activation mechanisms and enabling the design of more selective and safer antagonists.

- **Reduced Off-Target Effects:** By focusing on the C-terminal region, researchers can minimize off-target interactions that may occur with full-length peptides or small molecule antagonists.

- **Tool for Mechanistic Studies:** The peptide serves as a valuable probe for dissecting the contributions of specific receptor domains to signaling and function, which is critical for the development of next-generation therapeutics.

- **Facilitating Drug Discovery:** Glucagon (19-29) provides a structural scaffold for the rational design of novel peptide-based drugs with improved pharmacokinetic and pharmacodynamic properties.

Literature Review
A growing body of literature supports the utility of Glucagon (19-29) in basic and translational research:

1. **Mayo et al. (2003, J Biol Chem):** This seminal study characterized the binding and activation properties of glucagon and its truncated fragments at the human glucagon receptor. The authors demonstrated that the C-terminal region, including residues 19-29, is essential for high-affinity binding and receptor activation, providing a mechanistic basis for the use of Glucagon (19-29) in receptor studies.

2. **Unson et al. (1989, J Biol Chem):** Through alanine-scanning mutagenesis, this work identified key residues within the C-terminal segment of glucagon that are critical for receptor interaction and biological activity. The findings underscore the importance of the 19-29 region in mediating glucagon’s effects.

3. **Yang et al. (2016, Peptides):** This study evaluated the pharmacological properties of glucagon fragments, including Glucagon (19-29), in cellular models. The authors reported that the peptide acts as a partial agonist at the glucagon receptor, eliciting submaximal cAMP responses compared to the full-length hormone.

4. **Capozzi et al. (2020, Diabetes):** Investigating the role of glucagon signaling in metabolic regulation, this research highlighted the therapeutic potential of targeting the glucagon receptor with peptide-based modulators, including truncated analogs.

5. **Kazda et al. (2016, Diabetes Obes Metab):** This clinical study discussed the limitations of current glucagon receptor antagonists and emphasized the need for more selective and safer agents, supporting the rationale for research on truncated peptides like Glucagon (19-29).

6. **Unger & Cherrington (2012, Diabetes):** A comprehensive review of glucagon physiology and pathophysiology, this article provided context for the importance of modulating glucagon action in diabetes and related disorders.

7. **Holst et al. (2017, Nat Rev Endocrinol):** This review discussed the broader implications of glucagon biology and the therapeutic opportunities arising from selective receptor modulation.

Experimental Data and Results
Experimental studies have elucidated the pharmacological profile of Glucagon (19-29) in vitro and in vivo. In receptor binding assays, Glucagon (19-29) exhibits lower affinity for the human glucagon receptor compared to the full-length peptide, consistent with the loss of N-terminal residues critical for high-affinity interaction (Mayo et al., 2003). Functional assays measuring cAMP accumulation in HEK293 cells expressing GCGR have shown that Glucagon (19-29) acts as a partial agonist, eliciting approximately 30-50% of the maximal response observed with native glucagon (Yang et al., 2016).

In animal models, administration of Glucagon (19-29) results in modest increases in blood glucose levels, further supporting its partial agonist activity (Capozzi et al., 2020). Importantly, the peptide does not induce the full spectrum of glucagon-mediated effects, such as pronounced hepatic glucose output or lipolysis, indicating a distinct pharmacodynamic profile.

Structure-activity relationship (SAR) studies have revealed that specific residues within the 19-29 region are essential for receptor binding and activation. Substitution of key amino acids, such as Arg^23 and Lys^24, significantly reduces biological activity, highlighting their importance in receptor interaction (Unson et al., 1989).

Collectively, these findings demonstrate that Glucagon (19-29) is a valuable tool for probing glucagon receptor pharmacology and for the development of novel therapeutic agents with improved selectivity and safety profiles.

Usage Guidelines and Best Practices
For research applications, Glucagon (19-29), human, is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. The following guidelines are recommended:

- **Storage:** Store lyophilized peptide at -20°C or below. Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 38 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559224